These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 29945328

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?
    Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM.
    Ann Pharmacother; 2015 Jul; 49(7):777-83. PubMed ID: 25855705
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
    Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL, Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories.
    Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
    Al-Aieshy F, Malmström RE, Antovic J, Pohanka A, Rönquist-Nii Y, Berndtsson M, Al-Khalili F, Skeppholm M.
    Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
    [Abstract] [Full Text] [Related]

  • 10. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
    Shin H, Koh EH, Lee GW, Song HN, Kim HY, Park S.
    J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
    [Abstract] [Full Text] [Related]

  • 11. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
    Lim MS, Hayes R, Sharma A, Kitiponchai T, Mohamed M, Mcrae S.
    Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
    [Abstract] [Full Text] [Related]

  • 12. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
    Horinaka S, Sugawara R, Yonezawa Y, Ishimitsu T.
    Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
    Bookstaver DA, Sparks K, Pybus BS, Davis DK, Marcsisin SR, Sousa JC.
    Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J, Trujillo T, Fisher S, Ko A, Lind SE, Kiser TH.
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [Abstract] [Full Text] [Related]

  • 16. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
    Cini M, Legnani C, Testa S, Tripodi A, Cosmi B, Palareti G.
    Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.
    Boissier E, Senage T, Babuty A, Gouin-Thibault I, Rozec B, Roussel JC, Sigaud M, Ternisien C, Trossaert M, Fouassier M, Lakhal K.
    Anesth Analg; 2021 Mar 01; 132(3):707-716. PubMed ID: 32833716
    [Abstract] [Full Text] [Related]

  • 19. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L, Lukes J, Friedecky D, Zhanelova M, Nemcova M, Ulehlova J, Prochazkova J, Hlusi A, Palova M, Vaclavik J.
    Clin Lab; 2018 Oct 01; 64(10):1611-1621. PubMed ID: 30336535
    [Abstract] [Full Text] [Related]

  • 20. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
    Liu Z, Xie Q, Zhang H, Mu G, Zhou S, Wang Z, Jiang J, Xiang Q, Cui Y.
    Am J Cardiovasc Drugs; 2021 Nov 01; 21(6):669-679. PubMed ID: 34142346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.